Is Agios Pharmaceuticals Inc (AGIO) a Stock to Watch After Losing -1.93% This Week?

Agios Pharmaceuticals Inc (AGIO) stock is down 1.93% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Agios Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AGIO!

See Full AGIO Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With AGIO Stock Today?

Agios Pharmaceuticals Inc (AGIO) stock has fallen -0.02% while the S&P 500 has risen 1% as of 2:08 PM on Thursday, Jan 20. AGIO is lower by -$0.01 from the previous closing price of $31.03 on volume of 271,175 shares. Over the past year the S&P 500 has risen 20.51% while AGIO is lower by -33.34%. AGIO earned $22.57 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 1.37. To screen for more stocks like Agios Pharmaceuticals Inc click here.

More About Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. Click Here to get the full Stock Report for Agios Pharmaceuticals Inc stock.